Company intelligence / Profile preview

Electra Partners

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

ELA026 achieved 100% overall survival at 8 weeks in Phase 1b frontline treatment of malignancy-associated sHLH patients, compared to ~50% historical benchmark; ELA026 advancing to global pivotal Phase 2/3 trial in sHLH; ELA822 advancing to clinic.[1][2][5]

Therapeutic areas: HematologyImmunologyOncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Sanofi

Beyond the preview

Go deeper on Electra Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Electra Partners.

Explore the full profile